In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

William Looney

Executive Editor

New York, NY
Advertisement
Set Alert for Articles By William Looney

Latest From William Looney

Gene Therapy: Spark Charts A Course From Science To Payer And Patient Satisfaction

Gene therapy’s promise depends on the ecosystem now being built to deliver real product to patients – safely and at quantities that match the soaring expectations fed by the curative potential of the science. To assess the state of play, In Vivo talks to the man who leads the team responsible for bringing forward the first US-approved gene therapy to treat an incurable, inherited genetic condition: John Furey, chief operating officer of Spark Therapeutics

C-Suite Speaks Leadership

Spark Therapeutics: Calculating The Price Of A Cure

John Furey, chief operating officer of Spark Therapeutics, discusses how the company has created a value framework for the first US-approved gene therapy to treat an incurable, inherited genetic condition: Luxturna  (voretegene neparvovec-ryzl).  He also highlights the remaining access and reimbursement challenges for this novel gene therapy, which is approved specifically for treatment of inherited retinal blindness from a rare RPE65 gene mutation. 
Market Access Strategy

Treatments Beyond Treatment: ASCO's Expanding Vision of Cancer Care

Cancer's chief professional practice organization, the American Society of Clinical Oncology (ASCO), is working to transform the post-treatment pathway for survivors of cancer. It is part of an overall movement in the cancer community emphasizing the importance of making current treatments work better for more patients. 

Cancer Innovation

Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

Cancer Market Intelligence

Cancer Survivorship: The Stakes For Biopharma

The growing prominence of a 16-million-strong community of cancer survivors is having a significant long-term impact on the practice of oncology and the expectations of providers and patients toward the biopharma enterprise.  

Market Intelligence Cancer

Cancer Vaccines: Is There A Future Beyond Trial And Error?

Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.

Innovation ImmunoOncology
See All
Advertisement
UsernamePublicRestriction

Register